TISIDB

Summary
Symbol	P2RX5
Name	purinergic receptor P2X, ligand gated ion channel, 5
Aliases	P2X5; purinergic receptor P2X, ligand-gated ion channel, 5; P2X5R; ATP receptor subunit; ionotropic ATP rece ......
Chromosomal Location	17p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Multi-pass membrane protein.
Domain	PF00864 ATP P2X receptor
Function	Receptor for ATP that acts as a ligand-gated ion channel.

> Gene Ontology [ TOP ]
Biological Process	GO:0006816 calcium ion transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0007596 blood coagulation GO:0007599 hemostasis GO:0010522 regulation of calcium ion transport into cytosol GO:0010524 positive regulation of calcium ion transport into cytosol GO:0010959 regulation of metal ion transport GO:0014074 response to purine-containing compound GO:0019722 calcium-mediated signaling GO:0019932 second-messenger-mediated signaling GO:0032844 regulation of homeostatic process GO:0032846 positive regulation of homeostatic process GO:0033198 response to ATP GO:0035587 purinergic receptor signaling pathway GO:0035590 purinergic nucleotide receptor signaling pathway GO:0043270 positive regulation of ion transport GO:0046683 response to organophosphorus GO:0050817 coagulation GO:0050848 regulation of calcium-mediated signaling GO:0050850 positive regulation of calcium-mediated signaling GO:0050878 regulation of body fluid levels GO:0051480 regulation of cytosolic calcium ion concentration GO:0051924 regulation of calcium ion transport GO:0051928 positive regulation of calcium ion transport GO:0055074 calcium ion homeostasis GO:0060401 cytosolic calcium ion transport GO:0060402 calcium ion transport into cytosol GO:0070838 divalent metal ion transport GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:2000021 regulation of ion homeostasis
Molecular Function	GO:0001614 purinergic nucleotide receptor activity GO:0004931 extracellular ATP-gated cation channel activity GO:0005216 ion channel activity GO:0005230 extracellular ligand-gated ion channel activity GO:0005231 excitatory extracellular ligand-gated ion channel activity GO:0005261 cation channel activity GO:0015267 channel activity GO:0015276 ligand-gated ion channel activity GO:0016502 nucleotide receptor activity GO:0022803 passive transmembrane transporter activity GO:0022834 ligand-gated channel activity GO:0022836 gated channel activity GO:0022838 substrate-specific channel activity GO:0035381 ATP-gated ion channel activity GO:0035586 purinergic receptor activity
Cellular Component	GO:0005635 nuclear envelope GO:0005637 nuclear inner membrane GO:0005639 integral component of nuclear inner membrane GO:0031229 intrinsic component of nuclear inner membrane GO:0031300 intrinsic component of organelle membrane GO:0031301 integral component of organelle membrane GO:0031965 nuclear membrane GO:0044453 nuclear membrane part

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04020 Calcium signaling pathway hsa04080 Neuroactive ligand-receptor interaction
Reactome	R-HSA-139853: Elevation of cytosolic Ca2+ levels R-HSA-109582: Hemostasis R-HSA-418360: Platelet calcium homeostasis R-HSA-418346: Platelet homeostasis

Summary
Symbol	P2RX5
Name	purinergic receptor P2X, ligand gated ion channel, 5
Aliases	P2X5; purinergic receptor P2X, ligand-gated ion channel, 5; P2X5R; ATP receptor subunit; ionotropic ATP rece ......
Chromosomal Location	17p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between P2RX5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	P2RX5
Name	purinergic receptor P2X, ligand gated ion channel, 5
Aliases	P2X5; purinergic receptor P2X, ligand-gated ion channel, 5; P2X5R; ATP receptor subunit; ionotropic ATP rece ......
Chromosomal Location	17p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of P2RX5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	P2RX5
Name	purinergic receptor P2X, ligand gated ion channel, 5
Aliases	P2X5; purinergic receptor P2X, ligand-gated ion channel, 5; P2X5R; ATP receptor subunit; ionotropic ATP rece ......
Chromosomal Location	17p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of P2RX5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.18	0.755
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.079	0.929
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.274	0.742
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.572	0.264
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.222	0.87
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.022	0.58
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	1.419	0.0201
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.137	0.212
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.869	0.0584
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.06	0.932
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.018	0.985
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.272	0.298

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of P2RX5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	33.3	0	33.3	0.0365
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	50	0	50	0.109
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	P2RX5
Name	purinergic receptor P2X, ligand gated ion channel, 5
Aliases	P2X5; purinergic receptor P2X, ligand-gated ion channel, 5; P2X5R; ATP receptor subunit; ionotropic ATP rece ......
Chromosomal Location	17p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of P2RX5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	P2RX5
Name	purinergic receptor P2X, ligand gated ion channel, 5
Aliases	P2X5; purinergic receptor P2X, ligand-gated ion channel, 5; P2X5R; ATP receptor subunit; ionotropic ATP rece ......
Chromosomal Location	17p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of P2RX5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by P2RX5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	P2RX5
Name	purinergic receptor P2X, ligand gated ion channel, 5
Aliases	P2X5; purinergic receptor P2X, ligand-gated ion channel, 5; P2X5R; ATP receptor subunit; ionotropic ATP rece ......
Chromosomal Location	17p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of P2RX5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	P2RX5
Name	purinergic receptor P2X, ligand gated ion channel, 5
Aliases	P2X5; purinergic receptor P2X, ligand-gated ion channel, 5; P2X5R; ATP receptor subunit; ionotropic ATP rece ......
Chromosomal Location	17p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of P2RX5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	P2RX5
Name	purinergic receptor P2X, ligand gated ion channel, 5
Aliases	P2X5; purinergic receptor P2X, ligand-gated ion channel, 5; P2X5R; ATP receptor subunit; ionotropic ATP rece ......
Chromosomal Location	17p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between P2RX5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	P2RX5
Name	purinergic receptor P2X, ligand gated ion channel, 5
Aliases	P2X5; purinergic receptor P2X, ligand-gated ion channel, 5; P2X5R; ATP receptor subunit; ionotropic ATP rece ......
Chromosomal Location	17p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting P2RX5 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse P2RX5